Orthofix Medical raised its full-year 2026 net sales and adjusted EBITDA guidance after reporting second-quarter sales growth across its spine, limb reconstruction and therapeutic solutions businesses.
The company reported second-quarter net sales of $210.9 million, up 4% year over year on a reported basis. Global Spine Fixation and Global Limb Reconstruction each posted double-digit constant currency growth, while Therapeutic Solutions generated $64.2 million in net sales despite temporary Medicare reimbursement cuts during part of the quarter, according to an Aug. 5 earnings call.
Orthofix increased full-year 2026 net sales guidance to $845 million to $855 million, up from its previous range of $838 million to $848 million. The company also raised its adjusted EBITDA outlook to $95 million to $98 million from $90 million to $93 million.
The company said it expects continued growth in core businesses, though productivity challenges among smaller U.S. spine distributors are expected to persist through the remainder of the year.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
